How Rejuran and PDRN Polynucleotide Boosters Work: A Complete Mechanism Guide

Aug 17
5 min read

PDRN polynucleotide skin boosters are injectable treatments containing purified DNA fragments that act as a biological signal to stimulate fibroblast activity and support skin repair, rather than adding volume like a filler. Rejuran is the best-known brand of this category in Korea, but the mechanism belongs to the ingredient class, not the trade name. This distinction matters, because patients are frequently sold a brand without understanding what the molecule does, what it cannot do, and how many sessions are realistically required. This guide explains the biology in plain terms, sets out what the published evidence does and does not support, and describes how a polynucleotide course differs from hyaluronic acid boosters, collagen stimulators and energy devices.

What Polynucleotides and PDRN Actually Are

Polynucleotides are long chains of nucleotides, the building blocks of DNA. PDRN, or polydeoxyribonucleotide, refers to shorter purified DNA fragments, typically in the 50-1,500 kilodalton range, most commonly extracted and sterilised from salmon or trout sperm DNA because its sequence homology with human DNA is high and its immunogenic potential after purification is low. The material is not a hormone, not a growth factor concentrate, and not a filler. In regulatory terms in Korea these products are generally handled as medical devices or drugs depending on formulation, which is one reason marketing claims vary between clinics. Understanding that the active principle is a signalling molecule, not a volumising gel, resets expectations appropriately.

The Proposed Mechanism: Adenosine A2A Receptors and Salvage Pathway

Two mechanisms are described in the literature. The first is receptor-mediated: PDRN fragments are thought to act as agonists at the adenosine A2A receptor, which is associated with downregulation of pro-inflammatory signalling and upregulation of vascular endothelial growth factor, favouring angiogenesis and a more repair-oriented tissue environment. The second is the nucleotide salvage pathway: degraded fragments supply nucleosides and nucleotides that cells can reuse for DNA synthesis, reducing the metabolic cost of proliferation for fibroblasts under repair demand. The practical implication of both is the same. The treatment does not deposit a visible material; it attempts to shift cellular behaviour, so results appear gradually over weeks rather than immediately.

What the Evidence Supports, and What Remains Uncertain

Published work on PDRN includes controlled studies in wound healing, tendinopathy and diabetic foot ulcers, alongside a growing but smaller aesthetic dermatology literature reporting improvements in skin elasticity, hydration and fine wrinkle scores after multi-session courses. Reported findings are generally modest and incremental rather than transformative. Important limitations are common: many aesthetic studies are small, some are open-label, follow-up periods are frequently under 6 months, and industry involvement is not always fully disclosed. A reasonable reading is that polynucleotides appear to offer measurable but moderate improvement in skin quality with a favourable short-term safety profile, and that long-term durability data remain limited. Claims of permanent rejuvenation are not supported.

What It Treats Well, and What It Does Not Treat

Polynucleotide boosters are most reasonably positioned for skin quality concerns: fine crepey texture, dehydration, dullness, mild elasticity loss, periorbital fine lines and post-procedure recovery support. They are frequently used adjunctively after laser or microneedling. They are poorly matched to problems that require structural change. They will not lift descended tissue, will not correct significant volume loss, will not resolve deep static folds, and are not a substitute for photoprotection in pigmentation management. Presenting them as an alternative to a lifting device or to filler is a category error that produces disappointed patients. Where laxity is the dominant complaint, an energy-based or surgical option is the more honest comparison.

Protocol Reality: Session Count, Interval and Downtime

Typical clinical protocols involve an initial course of 3-4 sessions spaced 2-4 weeks apart, followed by maintenance every 4-6 months. Single-session results are usually described by patients as subtle, which is why courses are standard rather than upsell. Injection is performed as microdroplet or mesotherapy-style placement in the superficial dermis, sometimes with a mechanical injector. Expected immediate findings include visible papules or bumps that generally settle within 24-72 hours, pinpoint bruising in a minority of patients, and transient tenderness. Downtime is usually described as 1-3 days of social downtime. Patients with a needle-related vasovagal history, active skin infection, or fish protein allergy concerns should raise this before treatment.

Polynucleotides Versus HA Boosters, Collagen Stimulators and Devices

This comparison is where most clinic pages are vague. Hyaluronic acid skin boosters primarily hydrate by binding water and give a faster visible plumping effect, with duration typically measured in months. Collagen stimulators such as poly-L-lactic acid or calcium hydroxylapatite provoke a more aggressive neocollagenesis response with correspondingly greater potential for nodules and a slower, longer-lasting change. Energy devices including radiofrequency microneedling and fractional lasers act by controlled thermal injury and remodel deeper tissue. Polynucleotides sit closer to the gentle, repair-signalling end of the spectrum, with lower immediate drama and lower risk. They are often best used in combination with, rather than instead of, one of the others.

How to Evaluate a Clinic Offering This Treatment

Practical verification steps matter because product sourcing varies. Ask which specific product and concentration is being used and whether the packaging can be shown before injection; ask whether the injector is a physician and how many sessions the plan assumes; ask what the total course cost is rather than the per-session teaser price, since a quoted single-session figure multiplied by four is often the real cost; ask what happens if response is minimal after the full course; and ask for standardised before-and-after photography under fixed lighting at baseline and month 3. Treatments promoted with dramatic single-session photographs, or bundled aggressively at a first consultation, warrant additional scrutiny.

Frequently Asked Questions

How many polynucleotide sessions are needed before results appear?

Most protocols use 3-4 sessions at 2-4 week intervals, with changes in texture and hydration typically described from around the second or third session. Because the mechanism is a repair signal rather than a filler, immediate post-injection change is generally minimal.

Is PDRN safe for people with fish allergies?

Products are purified to remove protein, and reported allergic reactions are uncommon, but the DNA source is salmon or trout. Anyone with a known fish or seafood allergy should disclose it and discuss the specific product with the treating physician before proceeding.

How long do the results last?

Reported improvement in skin quality is generally described as lasting several months after a completed course, with maintenance commonly scheduled every 4-6 months. Long-term durability data beyond one year remain limited, so maintenance planning should be assumed rather than hoped against.

Can polynucleotide boosters be combined with laser or microneedling?

Combination is common in Korean practice, often with polynucleotides used after an energy-based treatment to support recovery. Sequencing and interval should be set by the treating physician, since injecting into acutely inflamed or compromised skin is generally avoided.

Is Rejuran the same as a filler?

No. Fillers add physical volume in a defined plane, whereas polynucleotide products aim to change cellular repair behaviour without volumising. Expecting contour change from a polynucleotide course is the most common source of patient dissatisfaction with this treatment.

Next Steps

If skin quality rather than volume or laxity is your primary concern, a polynucleotide course is a reasonable option to discuss, provided the plan is quoted as a full course and photographed under standardised conditions. Ask any clinic to state in writing which product is used, how many sessions the plan assumes, and what the review point is if response is minimal. Our coordination team can arrange multilingual dermatology consultations in Seoul and help you compare written treatment plans before committing.

Sources and Further Reading

Primary references consulted for this article: Korea Health Industry Development Institute (KHIDI) | Korean Medical Association (KMA) | PubMed: polydeoxyribonucleotide PDRN skin literature

This article is general information for international patients and is not medical advice. Individual suitability, risks and outcomes can only be determined by a licensed physician after in-person examination.